GENFLOW BIOSCIENCES PLC Total Liabilities
GENFLOW BIOSCIENCES PLC total liabilities. Based on the latest financial reports, GENFLOW BIOSCIENCES PLC (WQ5) has total liabilities worth €771.38K EUR (≈ $901.83K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See WQ5 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of GENFLOW BIOSCIENCES PLC (2021–2024)
Total liabilities of GENFLOW BIOSCIENCES PLC from 2021 to 2024. This chart illustrates how GENFLOW BIOSCIENCES PLC's total liabilities have evolved over time, based on quarterly financial data.
GENFLOW BIOSCIENCES PLC Competitors by Total Liabilities
The table below lists competitors of GENFLOW BIOSCIENCES PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SBC Corp Bhd
KLSE:5207
|
Malaysia | RM166.66 Million |
|
Elbit Imaging Ltd
TA:EMITF
|
Israel | ILA306.36 Million |
|
Les Hôtels de Paris SA
PA:HDP
|
France | €224.47 Million |
|
Minnova Corp
V:MCI
|
Canada | CA$5.40 Million |
|
AIM Commercial Growth Freehold And Leasehold Real Estate Investment Trust
BK:AIMCG
|
Thailand | ฿512.78 Million |
|
Bytes Technology Ltd
LSE:BYIT
|
UK | GBX393.01 Million |
|
Ostim Endustriyel Yatirimlar ve Isletme AS
IS:OSTIM
|
Turkey | TL399.06 Million |
|
Foxx Development Holdings Inc.
NASDAQ:FOXX
|
USA | $75.94 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down GENFLOW BIOSCIENCES PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GENFLOW BIOSCIENCES PLC asset portfolio.
Liquidity & Leverage Metrics
GENFLOW BIOSCIENCES PLC Total Liabilities Ratios Explained
GENFLOW BIOSCIENCES PLC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.65 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GENFLOW BIOSCIENCES PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GENFLOW BIOSCIENCES PLC (2021–2024)
The table below shows the annual total liabilities of GENFLOW BIOSCIENCES PLC from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €788.92K ≈ $922.33K |
+37.93% |
| 2023-12-31 | €571.96K ≈ $668.68K |
+127.88% |
| 2022-12-31 | €250.99K ≈ $293.43K |
+13.35% |
| 2021-12-31 | €221.43K ≈ $258.87K |
-- |
About GENFLOW BIOSCIENCES PLC
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducin… Read more